/
IMRN
$1.08-$0.02 (-1.82%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$8.9M
8M shares
52-week range
$0.68 – $2.39
24% from low
Exchange
NASDAQ
ADRC
Borrow rate
19.76%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-3.07
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.8M | $2.4M | $2.5M | $145.8K | $765.2K | $1.8M | $4.9M | $7.3M |
| Cost of revenue | $582.3K | $680.8K | $688.8K | $810.8K | $241.7K | $64.6K | $1.6M | $2.5M |
| Gross profit | $1.3M | $1.7M | $1.8M | −$665.1K | $523.5K | $1.7M | $3.3M | $4.8M |
| Gross margin | 68.4% | 71.5% | 72.6% | -456.2% | 68.4% | 96.4% | 68.1% | 65.4% |
| R&D | $2.3M | $1.0M | $1.2M | $1.4M | $657.7K | $2.6M | $5.4M | $3.6M |
| Operating income | −$3.0M | −$4.7M | −$2.9M | −$8.4M | −$2.9M | −$3.6M | −$5.8M | −$5.3M |
| EBITDA | −$3.2M | −$4.7M | −$3.1M | −$8.0M | −$3.1M | −$3.4M | −$5.2M | −$5.3M |
| Net income | −$3.0M | −$4.7M | −$2.9M | −$8.4M | −$2.9M | −$3.8M | −$6.9M | −$5.2M |
| Net margin | -163.4% | -195.0% | -116.2% | -5751.6% | -373.0% | -209.8% | -141.5% | -71.6% |
| EPS (diluted) | -0.90 | -1.29 | -0.66 | -1.52 | -0.50 | -0.66 | -1.22 | -0.90 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $8M | $-0.01 | $-0.01–$-0.01 | 1 |
| 2027 | $9M | $-0.02 | $-0.02–$-0.02 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Immuron Limited American Depositary Shares
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.
www.immuron.com.au- Employees
- 7
- IPO / List date
- Dec 13, 2007
Held by traders on TradeandTell
No one on the platform currently holds IMRN.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in IMRN as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded IMRN yet.
